Recurrent angioedema associated with hypogonadism or anti-androgen therapy.
Two male patients with hypogonadism and four female patients who received an anti-androgen as contraceptive (cyproteronacetate) and who had recurrent angioedema are described. In one male patient, augmentation of the plasma androgen level resulted in disappearance of symptoms. In the four female patients, recurrent angioedema and urticaria developed after initiation of the anti-androgen treatment. Cessation of cyproteronacetate and a change to another contraceptive resulted in complete resolution of the previously frequent angioedematous attacks. The women are still symptom free after more than 60 patient's months. These cases suggest that an androgen deficit due to either hypogonadism or to anti-androgen treatment may be another cause of angioedema. One of the two male patients was untreated and presented with 40% normal value of C1-INH. Androgen therapy normalized C1-INH concentration in this male patient. Functional C1-INH in the same patient, studied before and after the beginning of androgen therapy, clearly increased when assessed by inhibition of amidolytic activity of C1-esterase. The other male patient with hypogonadism had already been under androgen treatment for 4 years and had C1-INH levels in the normal range. In the female patients, complement profiles were normal before and after cessation of anti-androgen contraception; however, the C1-INH plasma levels were higher after cessation of anti-androgen anticonception. These results indicate an effect of androgen deficit on the level of C1-INH in circulating plasma but do not prove a role of C1-INH in angioedema associated with diminished androgen plasma levels.
Pichler
W J
WJ
Institute of Clinical Immunology, Inselspital, Bern, Switzerland.
Lehner
R
R
Späth
P J
PJ
D000328:Adult; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000799:Angioedema / Q000150:complications* / Q000188:drug therapy; D003174:Complement C1 Inactivator Proteins; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017373:Cyproterone Acetate; D005260:Female; D006801:Humans; D007006:Hypogonadism / Q000150:complications*; D008297:Male
D000726:Androgen Antagonists; D003174:Complement C1 Inactivator Proteins; D017373:Cyproterone Acetate; D003534:Cyproterone